Publication

Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy study.
Bareng APN, Wu KW, Takashima E, Argyropoulos DC, Smith L, Naung MT, Mazhari R, Schoffer K, Kiernan-Walker N, Abraham A, Lamont M, Mehra S, Lim PS, Sattabongkot J, Monteiro W, Lacerda M, Healer J, Chitnis CE, Tham WH, Tsuboi T, Mueller I, Barry AE, Longley RJ.
Lancet Microbe. 2026 Jun;7(6):101335. doi: 10.1016/j.lanmic.2025.101335. Epub 2026 May 19.
PMID: 42155491

IgG and IgM responses to PfEMP1 domains associated with semi-immunity to clinical malaria in Burkinabe children under five.
Dankyi BO, Yuguchi T, Rojrung R, Nagaoka H, Kanoi BN, Tiono AB, Nebie I, Ouedraogo A, Tanaka K, Miyake Y, Miura K, Sattabongkot J, Sirima SB, Tsuboi T, Takashima E.
Front Immunol. 2026 Apr 2;17:1781670. doi: 10.3389/fimmu.2026.1781670. eCollection 2026.
PMID: 42004967

TgJosephin and TgRad23 are important for anti-IFN-γ virulence via deubiquitination of SPM1 in Toxoplasma.
Hashizaki E, Tachibana Y, Fukumoto J, Takashima E, Kosako H, Okuzaki D, Sasai M, Yamamoto M.
mSphere. 2026 May 26;11(5):e0013726. doi: 10.1128/msphere.00137-26. Epub 2026 Apr 13.
PMID: 41972766

An in vivo fitness gene of Toxoplasma, MIC11, is essential for PLP1-mediated egress from host cells.
Tachibana Y, Gu X, Sasai M, Kosako H, Takashima E, Standley DM, Carruthers VB, Soldati-Favre D, Yamamoto M.
Nat Commun. 2026 Apr 4;17(1):4895. doi: 10.1038/s41467-026-71423-x.
PMID: 41935076

A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria.
Opi DH, Longley RJ, Takashima E, Spelman T, Tayipto Y, Schoffer K, Brewster J, Reiling L, Wines BD, Kiniboro B, Siba P, Harbers M, Hogarth M, Tsuboi T, Robinson LJ, Mueller I, Beeson JG.
Immunity. 2026 Mar 10;59(3):783-797.e4. doi: 10.1016/j.immuni.2026.02.003. Epub 2026 Feb 26.
PMID: 41759513

Identification of a growth-inhibitory epitope in PfRipr5, a malaria vaccine candidate against Plasmodium falciparum.
Nagaoka H, Fukushima A, Tsuboi T, Takashima E.
Front Immunol. 2026 Jan 27;17:1724796. doi: 10.3389/fimmu.2026.1724796. eCollection 2026.
PMID: 41676142

A lysine-free REC tag system for proximity-biotinylation applications.
Tokunaga S, Nagaoka H, Ozawa T, Yamada K, Takeda H, Fujisaki H, Hamada M, Soga F, Kishi H, Takashima E, Sawasaki T.
Sci Rep. 2026 Jan 8;16(1):4846. doi: 10.1038/s41598-026-35323-w.
PMID: 41507514

Pfs230 domain 12 is a potent malaria transmission-blocking vaccine candidate.
Inklaar MR, de Jong RM, Da DF, Hubregtse LL, Meijer M, Teelen K, Bekkering ET, Grievink S, van de Vegte-Bolmer M, van Gemert GJ, Stoter R, Nagaoka H, Tsuboi T, Takashima E, Spruijt CG, Vermeulen M, Dabire RK, Arinaitwe E, Cohuet A, Bousema T, Jore MM.
Sci Adv. 2025 Nov 7;11(45):eadw8216. doi: 10.1126/sciadv.adw8216. Epub 2025 Nov 7.
PMID: 41202138

Pfs230 Domains 7-10 Encoded by DNA Vaccines Induce Potent Complement-Independent Transmission-Blocking Antibody Against Plasmodium falciparum.
Cao Y, Hayashi CTH, Tripathi AK, Takashima E, Tsuboi T, Harju TB, Kumar N.
J Infect Dis. 2026 May 15;233(5):912-923. doi: 10.1093/infdis/jiaf555.
PMID: 41172338

Plasmodium falciparum Liver Stage Antigen 3 plays a role in completing the final stages of merozoite invasion of red blood cells.
Morita M, Jennison C, O'Neill MT, Kanoi BN, Ishino T, Tsuboi T, Boddey JA, Takashima E.
Int J Parasitol. 2026 May;56(5):104743. doi: 10.1016/j.ijpara.2025.10.003. Epub 2025 Oct 22.
PMID: 41135800